Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757665 | 0.95 | PTGDR2 (0.78) | PTGDR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2206147 | 0.91 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1757764 | 0.90 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL1757750 | 0.90 | PTGDR2 (0.94) | PTGDR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1757726 | 0.90 | PTGDR2 (0.78) | PTGDR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1757568 | 0.90 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL1757812 | 0.89 | PTGDR2 (0.79) | PTGDR2CYP2C9 | |
| SCHEMBL1757613 | 0.89 | PTGDR2 (0.79) | PTGDR2 | |
| SCHEMBL1757801 | 0.88 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL1757466 | 0.88 | PTGDR2 (0.78) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | claimed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885CYP1A2 879/4885CYP3A4 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.